BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. Beijing Chieftain Control Engineering Technology Co., Ltd. Share Price
Equities
300430
CNE100001YS5
Industrial Machinery & Equipment
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.06 CNY | +6.30% |
|
+16.29% | +26.38% |
| Sales 2024 * | 1.39B 193M 15.35B | Sales 2025 * | 1.64B 227M 18.08B | Capitalization | 5.1B 705M 56.2B |
|---|---|---|---|---|---|
| Net income 2024 * | 222M 30.66M 2.44B | Net income 2025 * | 288M 39.78M 3.17B | EV / Sales 2024 * | 3.66 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.11 x |
| P/E ratio 2024 * |
22.3
x | P/E ratio 2025 * |
17.2
x | Employees | 1,665 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.69% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.30% | ||
| 1 week | +16.29% | ||
| Current month | +1.46% | ||
| 1 month | +13.73% | ||
| 3 months | +49.50% | ||
| 6 months | +14.09% | ||
| Current year | +26.38% |
1 week
14.98
18.16
1 month
13.6120.17
Current year
7.8520.17
1 year
7.8520.17
3 years
7.8520.17
5 years
6.7020.17
10 years
6.5048.44
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Liang
CEO | Chief Executive Officer | 50 | 09/06/20 |
Kai Liang
FOU | Founder | 55 | 21/07/03 |
Zhen Hua Lu
DFI | Director of Finance/CFO | 49 | 30/06/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kai Liang
FOU | Founder | 55 | 21/07/03 |
Fu Qing Wang
BRD | Director/Board Member | 61 | 30/04/11 |
Yuan Long Luo
BRD | Director/Board Member | 52 | 25/05/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 18.06 | +6.30% | 13,431,880 |
| 25/04/24 | 16.99 | +0.30% | 10,923,460 |
| 24/04/24 | 16.94 | +3.74% | 11,125,480 |
| 23/04/24 | 16.33 | +7.36% | 11,279,560 |
| 22/04/24 | 15.21 | -2.06% | 9,038,928 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Beijing Chieftain Control Engineering Technology Co., Ltd. is a China-based company primarily engaged in the provision of medical and biological industrial automation control system integrated solutions. The Company focuses on automation control applications in the production process of pharmaceutical and biotechnology products, and provides automation control system products and integrated solutions to large and medium sized pharmaceutical, biotechnology companies, based on independent research and development of core technologies and independent produced key equipment and components. Its main products include four series: Fermentation and Synthesis, Purification, Product Preparation, as well as Auxiliary Process.
Calendar
28/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
18.06
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.38% | 680M | |
| +12.65% | 82.35B | |
| +19.97% | 71.09B | |
| +20.92% | 37.73B | |
| +15.55% | 32.01B | |
| +9.19% | 27.2B | |
| +4.28% | 26.74B | |
| +3.99% | 26B | |
| +13.27% | 25.5B | |
| +17.10% | 24.76B |
- Stock Market
- Equities
- 300430 Stock
